Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05917522 · ClinicalTrials.gov registry record · Phase 2
Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation
A Phase 2 study of Kidney Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 800
- Enrollment target
- 15
- Study locations
NCT05917522 is a Phase 2 study of Kidney Transplant that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 800 participants, below the 1,872-participant average among 30 other Kidney Transplant trials with a reported enrollment target (57% lower). The trial reports 15 study locations across 13 states.
The verdict
NCT05917522, a Phase 2 study of Kidney Transplant, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 800 participants
- Enrollment target
- 15
- Study locations
Study Summary
800 adult first time kidney transplant recipients will be enrolled in the Observational Study and followed to evaluate their Human Leukocyte Antigen (HLA)-DR/DQ molecular mismatch (mMM) score as a risk-stratifying prognostic biomarker. Six months after transplant the study will identify those who meet the eligibility criteria for the Nested Randomized Control Trial (RCT). 300 eligible subjects will be randomized 2:1 to abatacept or Standard of care (SOC) in the randomization and followed for 18 months monitoring for safety and improvement in renal function, neurocognitive function, and a life participation patient reported outcome measure (PROM). The primary objective of the Observational Study is to test the validity of the HLA-DR/DQ mMM score as a prognostic biomarker for stratification of post-transplant alloimmune risk. Whereas the objective of the Nested RCT is to test whether a superior outcome in kidney function (primary endpoint), as well as secondary endpoints (neurocognitive function, and life participation PROM), will be achieved in patients who are transitioned from Tacrolimus (TAC) to abatacept, while maintaining efficacy (freedom from biopsy proven acute rejection).
Conditions Studied
Interventions
- BIOLOGICAL Abatacept
- PROCEDURE Standard of Care at US Transplant Centers
Study Locations (15)
California
- Cedars Sinai Medical Center: Transplantation - Los Angeles
- Ronald Reagan UCLA Medical Center: Transplantation - Los Angeles
Pennsylvania
- University of Pennsylvania Medical Center: Transplantation - Philadelphia
- University of Pittsburgh Medical Center: Transplantation - Pittsburgh
Alabama
- University of Alabama School of Medicine: Transplantation - Birmingham
Connecticut
- Yale University, School of Medicine: Transplantation - New Haven
Maryland
- Johns Hopkins Hospital:Transplantation - Baltimore
Massachusetts
- Massachusetts General Hospital: Transplantation - Boston
Minnesota
- Mayo Clinic Rochester: Transplantation - Rochester
Missouri
- Washington University School of Medicine in St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2023-12-07 |
| Est. Completion | 2029-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05917522
The ClinicalTrials.gov registry entry for NCT05917522 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,872-participant average among 30 other Kidney Transplant trials with a reported enrollment target (57% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Transplant appearing as the primary indexed condition, and to 2 interventions - of which Abatacept is the first listed.
NCT05917522 reports 15 study locations spanning 13 distinct geographic areas - top geographies include California, Pennsylvania, Alabama.
Frequently Asked Questions
What is clinical trial NCT05917522 about?
NCT05917522 is a clinical study titled "Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation". 800 adult first time kidney transplant recipients will be enrolled in the Observational Study and followed to evaluate their Human Leukocyte Antigen (HLA)-DR/DQ molecular mismatch (mMM) score as a risk-stratifying prognostic biomarker. Six months after transplant the study will identify those who me...
What is the current status of trial NCT05917522?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 800 participants. The study started on 2023-12-07. Estimated completion is 2029-07.
What conditions does trial NCT05917522 study?
This clinical trial studies the following conditions: Kidney Transplant.
What interventions are being tested in trial NCT05917522?
The interventions under investigation include: Abatacept (BIOLOGICAL), Standard of Care at US Transplant Centers (PROCEDURE).
Who is sponsoring clinical trial NCT05917522?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05917522 being conducted?
This trial has 15 study locations across Alabama, California, Connecticut, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Advancing Transplantation Outcomes in Children
RECRUITING · Phase 2
-
Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)
RECRUITING · Phase 2
-
Sotagliflozin Safety and Tolerability Among Renal Transplant Recipients
COMPLETED · Phase 2
-
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
COMPLETED · Phase 2
-
COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study
COMPLETED · Phase 2
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.